Non-FDG-avid primary papillary thyroid carcinoma may not differ from FDG-Avid papillary thyroid carcinoma

Thyroid

Volumn 23, Issue 11, 2013, Pages 1452-1460

  Kim, Min Hee ^a   Ko, Sun Hee ^a   Bae, Ja Seong ^b   Lee, Sung Hak ^c   Jung, Chan Kwon ^c   Lim, Dong Jun ^a   Baek, Ki Hyun ^a   Kim, Sung Hoon ^d   Lee, Jong Min ^a   Kang, Moo Il ^a   Cha, Bong Yun ^a  

^a Sungkyunkwan University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Hospital Pathology   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SIZE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; TUMOR CALCINOSIS;

ADULT; AGED; CARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; MUTATION; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS B-RAF; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84887421706     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2013.0051     Document Type: Article

References (51)

1. Warburg O 1956 On the origin of cancer cells. Science 123: 309-314.
2. Buerkle A, Weber WA 2008 Imaging of tumor glucose utilization with positron emission tomography. Cancer Metastasis Rev 27:545-554.
3. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW 2007 The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110:1738-1744. (Pubitemid 47557298)
4. Kornberg A, Freesmeyer M, Bä rthel E, Jandt K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D, Settmacher U 2009 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 9:592-600.
5. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW 2010 Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer 116:1469-1475.
6. Macheda ML, Rogers S, Best JD 2005 Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202:654-662. (Pubitemid 40175840)
7. Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, Seki H, Oguchi M, Taki S, Nambu Y, Tonami H, Katsuda S, Yamamoto I 2000 Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med 27:1778-1785.
8. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF 2002 Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379-387. (Pubitemid 34072519)
9. de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, Boerman OC, Oyen WJ 2007 Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 55:79-87. (Pubitemid 46038871)
10. Westerterp M, Sloof GW, Hoekstra OS, Ten Kate FJ, Meijer GA, Reitsma JB, Boellaard R, van Lanschot JJ, Molthoff CF 2008 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol 134:227-236. (Pubitemid 350234068)
11. Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC 2009 Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun 30:594-601.
12. van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, Rupa D, Pastorekova S, Stroobants S, Buell U, Lambin P, Vansteenkiste J, De Ruysscher D 2007 The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 43:1392-1398. (Pubitemid 46874072)
13. Shaw RJ 2006 Glucose metabolism and cancer. Curr Opin Cell Biol 18:598-608. (Pubitemid 44692479)
14. Ayala FR, Rocha RM, Carvalho KC, Carvalho AL, da Cunha IW, Lourenco SV, Soares FA 2010 GLUT1 and GLUT3 as potential prognostic markers for oral squamous cell carcinoma. Molecules 15:2374-2387.
15. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, Slater G, Weiss A, Burstein DE 1998 GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83:34-40. (Pubitemid 28299626)
16. Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, Honma K, Suzuki T 2001 Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 92:634-641. (Pubitemid 32735200)
17. Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, Jeong SY, Kim SW 2003 Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88:4100-4104. (Pubitemid 37153705)
18. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
19. Vriens D, de Wilt JH, van der Wilt GJ, Netea-Maier RT, Oyen WJ, de Geus-Oei LF 2011 The role of [(18) F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer 117:4582-4594.
20. Mitchell JC, Grant F, Evenson AR, Parker JA, Hasselgren PO, Parangi S 2005 Preoperative evaluation of thyroid nodules with 18FDG-PET/CT. Surgery 138:1166-1174; discussion 1174-1175.
21. Traugott AL, Dehdashti F, Trinkaus K, Cohen M, Fialkowski E, Quayle F, Hussain H, Davila R, Ylagan L, Moley JF 2010 Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18Ffluorodeoxyglucose positron emission tomography: interim analysis. World J Surg 34:1247-1253.
22. Yun M, Noh TW, Cho A, Choi YJ, Hong SW, Park CS, Lee JD, Kim CK 2010 Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor. J Clin Endocrinol Metab 95:3182-3188.
23. Hoang JK, Lee WK, Lee M, Johnson D, Farrell S 2007 US Features of thyroid malignancy: pearls and pitfalls. Radiographics 27:847-860; discussion 861-865.
24. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, Harris AL 2001 Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 85:881-890. (Pubitemid 33010557)
25. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI 2002 Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95:1055-1063. (Pubitemid 34925357)
26. Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis E, Harris AL 2006 Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24:727-735. (Pubitemid 46622039)
27. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS, Ogino S 2010 HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 176:2292-2301.
28. Kim BH, Lee CH, Kim SJ, Jeon YK, Kim SS, Kim YK, Kim IJ 2013 Clinicopathologic characteristics of synchronous primary thyroid cancer detected by initial staging 18F-FDG PET-CT examination in patients with underlying malignancy. Thyroid 23:1431-1437.
29. Choi JW, Yoon YH, Kim SM, Koo BS 2011 Characteristics of primary papillary thyroid carcinoma with false-negative findings on initial (18)F-FDG PET/CT. Ann Surg Oncol 18:1306-1311.
30. Buck AK, Schirrmeister H, Mattfeldt T, Reske SN 2004 Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 31(Suppl 1):S80-87. (Pubitemid 38833036)
31. Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, Tatsumi M, Sekimoto M, Hatazawa J, Nishimura T, Monden M 2006 Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D- glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 51:2198-2205.
32. Li M, Sun Y, Liu Y, Han A, Zhao S, Ma L, Zheng J, Yu J 2010 Relationship between primary lesion FDG uptake and clinical stage at PET-CT for non-small cell lung cancer patients: an observation. Lung Cancer 68:394-397.
33. Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K 2008 Standardized uptake values of uterine leiomyoma with 18F-FDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI. Ann Nucl Med 22:505-512.
34. Jeong HS, Chung M, Baek CH, Ko YH, Choi JY, Son YI 2006 Can [18F]-fluorodeoxyglucose standardized uptake values of PET imaging predict pathologic extrathyroid invasion of thyroid papillary microcarcinomas Laryngoscope 116: 2133-2137. (Pubitemid 44912307)
35. Bae JS, Chae BJ, Park WC, Kim JS, Kim SH, Jung SS, Song BJ 2009 Incidental thyroid lesions detected by FDG-PET/CT: prevalence and risk of thyroid cancer. World J Surg Oncol 7:63.
36. Geworski L, Knoop BO, de Cabrejas ML, Knapp WH, Munz DL 2000 Recovery correction for quantitation in emission tomography: a feasibility study. Eur J Nucl Med 27:161-169. (Pubitemid 30102021)
37. Nakamoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM, Wahl RL 2005 Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 234:879-885. (Pubitemid 40250832)
38. Buchmann I, Haberkorn U, Schmidtmann I, Brochhausen C, Buchholz HG, Bartenstein P, Hansen T 2008 Influence of cell proportions and proliferation rates on FDG uptake in squamous-cell esophageal carcinoma: a PET study. Cancer Biother Radiopharm 23:172-180. (Pubitemid 351630189)
39. Kaneko K, Abe K, Baba S, Tanabe Y, Yabuuchi H, Hatakenaka M, Sasaki M, Honda H 2010 Can calcification predict 131I accumulation on metastatic lymph nodes in papillary thyroid carcinoma patients receiving 131I therapy Comparison of CT, 131I WBS and 18F-FDG PET/CT. Eur Radiol 20:477-483.
40. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ 2000 Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107-1113. (Pubitemid 32269357)
41. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505. (Pubitemid 43236915)
42. Yen TC, See LC, Lai CH, Yah-Huei CW, Ng KK, Ma SY, Lin WJ, Chen JT, Chen WJ, Lai CR, Hsueh S 2004 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med 45:22-29. (Pubitemid 47611604)
43. Schonberger J, Ruschoff J, Grimm D, Marienhagen J, Rummele P, Meyringer R, Kossmehl P, Hofstaedter F, Eilles C 2002 Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid 12:747-754.
44. Kim YW, Do IG, Park YK 2006 Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas. Pathol Res Pract 202:759-765. (Pubitemid 44575893)
45. Kim BH, Kim IJ, Kim SS, Kim SJ, Lee CH, Kim YK 2010 Relationship between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in incidentally detected thyroid cancer. Cancer Biother Radiopharm 25:309-315.
46. Yasuda M, Ogane N, Hayashi H, Kameda Y, Miyagi Y, Iida T, Mori Y, Tsukinoki K, Minematsu T, Osamura Y 2005 Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol Rep 14:1499-1504.
47. Ciampi R, Vivaldi A, Romei C, Del Guerra A, Salvadori P, Cosci B, Pinchera A, Elisei R 2008 Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol 291:57-62.
48. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL 2000 The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157:411-421. (Pubitemid 30626905)
49. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter KC, Harris AL 2002 Hypoxiainducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-andneck cancer. Int J Radiat Oncol Biol Phys 53:1192-1202. (Pubitemid 34787855)
50. Giatromanolaki A, Sivridis E, Kouskoukis C, Gatter KC, Harris AL, Koukourakis MI 2003 Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Melanoma Res 13:493-501. (Pubitemid 37266952)
51. Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V 2010 BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer. Mod Pathol 23:1052-1060.